From the Department of Pediatric Nephrology, Gazi University, Ankara, Turkey.
Exp Clin Transplant. 2022 May;20(Suppl 3):112-114. doi: 10.6002/ect.PediatricSymp2022.O35.
Encapsulated peritoneal sclerosis is a rare complication of long-term peritoneal dialysis that has a high rate of morbidity and mortality. We present an 18-year-old female patient who was first diagnosed with renal failure at 8 years of age and who had 7 years of peritoneal dialysis and then hemodialysis before kidney transplant from a deceased donor. Before transplant, the patient developed encapsulated peritoneal sclerosis and was treated with tamoxifen and steroids. Three years after transplant, the patient presented with complaints of vomiting, abdominal pain, and abdominal distension and was again diagnosed with encapsulated peritoneal sclerosis. The patient required excretory paracentesis, pulse steroid treatment for 3 days, and treatment with methylprednisone and tamoxifen, which resulted in regression of signs and symptoms. Factors such as long-term peritoneal dialysis, a history of bacterial peritonitis, and use of high-concentration dialysate may cause encapsulated peritoneal sclerosis, but symptoms can recur after transplant, as shown in our patient. Thus, it is important to recognize that encapsulated peritoneal sclerosis may cause graft loss due to the various complications that it can cause.
包裹性腹膜硬化症是长期腹膜透析的一种罕见并发症,具有较高的发病率和死亡率。我们报告了一位 18 岁的女性患者,她在 8 岁时首次被诊断为肾衰竭,并接受了 7 年的腹膜透析和随后的血液透析,最后接受了来自已故供体的肾移植。移植前,该患者发生包裹性腹膜硬化症,并接受了他莫昔芬和类固醇治疗。移植后 3 年,患者出现呕吐、腹痛和腹胀的症状,再次被诊断为包裹性腹膜硬化症。患者需要进行排泄性腹腔穿刺术,3 天的脉冲类固醇治疗,以及甲基强的松龙和他莫昔芬治疗,这导致症状和体征消退。长期腹膜透析、细菌性腹膜炎病史和使用高浓度透析液等因素可能导致包裹性腹膜硬化症,但如我们的患者所示,其症状在移植后可能会复发。因此,重要的是要认识到包裹性腹膜硬化症可能会因它引起的各种并发症导致移植物丢失。